Supporting virtual clinical trials with laboratory services that focus on easing patient and site burden by way of innovative self-collection technology.
In February 2021, we published an article in Applied Clinical Trials titled "Self-collection of Blood Specimens in Clinical Trials", detailing how the pandemic spurred interest in decentralized clinical trial (DCT) approaches, such as the use of blood self-collection devices to allow a clinical trial participant to collect their own blood without having to visit an investigator site or have a healthcare worker visit them at home. We then moved on to talk about novel self-collection devices and the operational and patient burden issues that come along with them.
Since then, we have continued to perform scientific and operational feasibility studies to determine how we could make a safety testing panel available in clinical trials via at-home self-collection of blood specimens. At the time of publication, we have successfully completed the validation report for a 7-analyte liver safety panel.
Read the Applied Clinical Trials article by Q2 Solutions’ authors Chuck Drucker, Charlie Fix, Patrice Hugo, PhD, Julia Beck, PhD, Steven Lobel, PhD, D-ABMLI, MBA, FACB, John Corcoran, Viren Patel, PhD. This article focuses on our achievements in creating the first ever self-collection 7-analyte liver safety panel to support virtual clinical trials via the Tasso+ device. With the goal of making more tests accessible and easing patient and site burden through self-collection approaches in clinical trials and healthcare, several of our clinical trial testing and commercial diagnostic testing colleagues are performing feasibility studies related to various types of tests.
Download the article
